pargyline has been researched along with Autoimmune Diabetes in 1 studies
Pargyline: A monoamine oxidase inhibitor with antihypertensive properties.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Oral pargyline treatment protected transplanted beta cells in diabetic mice, thus leading to disease reversal." | 1.56 | Genome-scale in vivo CRISPR screen identifies RNLS as a target for beta cell protection in type 1 diabetes. ( Cai, EP; Hollister-Lock, J; Hou, S; Ishikawa, Y; Kiaf, B; Kissler, S; Leite, NC; Li, J; Melton, DA; Schiffer, CA; Yi, P; Yilmaz, NK; Zhang, W, 2020) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cai, EP | 1 |
| Ishikawa, Y | 1 |
| Zhang, W | 1 |
| Leite, NC | 1 |
| Li, J | 1 |
| Hou, S | 1 |
| Kiaf, B | 1 |
| Hollister-Lock, J | 1 |
| Yilmaz, NK | 1 |
| Schiffer, CA | 1 |
| Melton, DA | 1 |
| Kissler, S | 1 |
| Yi, P | 1 |
1 other study available for pargyline and Autoimmune Diabetes
| Article | Year |
|---|---|
Genome-scale in vivo CRISPR screen identifies RNLS as a target for beta cell protection in type 1 diabetes.
Topics: Animals; Autoimmunity; CRISPR-Cas Systems; Diabetes Mellitus, Type 1; Endoplasmic Reticulum Stress; | 2020 |